【摘要】：正達(dá)比加群酯(dabigatran etexilate)是一種新型口服抗凝藥物(NOACs),2010年獲得美國食品和藥物管理局(FDA)批準(zhǔn)用于預(yù)防非瓣膜性房顫患者卒中和全身性栓塞,2013年在中國上市~([1])。達(dá)比加群酯是前體藥物,口服后經(jīng)酯酶水解釋放出活性成分達(dá)比加群而發(fā)揮抗凝作用。雖然達(dá)比加群酯屬于直接凝血酶抑制劑,具有靶點(diǎn)單一、安全性好,無需特殊用藥監(jiān)測(cè)等優(yōu)勢(shì),有望取代華法
[Abstract]:(dabigatran etexilate) is a new oral anticoagulant drug, which was approved by the US Food and Drug Administration (FDA) in 2010 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It was listed in China in 2013. Darbine-group ester is a precursor drug, which is released by esterase hydrolysis to play an anticoagulant effect. Although Darby + group ester is a direct thrombin inhibitor with single target, good safety and no need for special drug monitoring, it is expected to replace the Chinese method.
【作者單位】： 南昌大學(xué)第二附屬醫(yī)院藥學(xué)部;南昌大學(xué)第二附屬醫(yī)院心血管內(nèi)科;
【基金】：“十二五”計(jì)劃國家科技重大專項(xiàng)課題“心血管疾病抗凝藥物臨床評(píng)價(jià)技術(shù)平臺(tái)建設(shè)”(2014ZX09303305)
【分類號(hào)】：R573.2
，

本文編號(hào)：2215865